New data presented at EULAR 2025 show Sam’s rapid user growth and increasing importance to patients.
At the American College of Rheumatology (ACR) Annual Meeting in Washington, DC, Steritas released the first engagement data for Sam (steroidsandme.com) - a first-in-class digital companion designed to support patients on their steroid journeys. Now, just six months later, new data presented at the European Congress of Rheumatology (EULAR 2025) highlight accelerating adoption and reach.[1]
The poster details how Sam’s audience has grown to over 4,000 users, with increasing depth of patient engagement and widespread uptake across disease areas.
Designed with input from clinicians, patients, advocacy groups, and industry leaders, Sam addresses the long-standing gap in patient education around steroid safety. Engagement over the first 12 months is notable:
- 4,012 users to date
- 350 times longer engagement than global averages
- 5% registration rate, twice the global benchmark
- 91% of all activity focused on patient education
Adoption is particularly strong among patients with inflammatory and rare diseases, where steroid-toxicity education remains a highly unmet need.
What patients are learning and logging
Patients are actively using Sam’s modules and tracking tools to monitor their experience on steroids. Highlights from the data include:
- Registered users log an average of 4.3 side effects
- Most frequently recorded concerns: fatigue, mental health, and appearance-related changes
- Most read content: Why We Taper and Talking to My Doctor, with over 680 users reading an average of 8 articles
This behavior highlights Sam’s growing role as a tool for preparing patients to have more informed, productive conversations with their healthcare providers.
Building credibility and visibility
In the year since its EULAR 2024 debut, Sam has been adopted by prominent advocacy groups including the Vasculitis Foundation, Lupus Research Alliance, and Foundation for Sarcoidosis Research. These partnerships, combined with increased search engine visibility, have driven further growth.
This fusion of clinical authority and accessible design and language is establishing Sam as a trusted companion for patients prescribed long-term glucocorticoid therapy.
As Sam continues to expand its reach across diseases, devices, and demographics, the newly presented EULAR 2025 data underscore its rising influence. With ongoing support from advocacy groups and a growing base of engaged users, Sam is poised to transform how patients approach their steroid journeys through shared decision-making.
You can request access to a high-resolution copy of the poster by clicking the button below.